They should be upgrading their FY21 guidance again at this upcoming half year results. In their August trading / guidance update, they assume "that global hospitalisations requiring respiratory support steadily return to normal by the end of this calendar year."
We know that this is outdated now.
Given RESMED's stellar price performance after their Q1 trading update, this should be a cracker of a result. The WAM (Wilson Asset Management) stable of funds have also increased their holdings in FPH (when comparing their month to month reports) despite FPH's sky high P/E ratio.
They should be upgrading their FY21 guidance again at this...
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add FPH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$28.82 |
Change
-0.090(0.31%) |
Mkt cap ! $16.83B | |||
| Open | High | Low | Value | Volume |
| $28.70 | $28.85 | $28.32 | $35.46M | 1.238M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 10792 | $28.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $28.83 | 2342 | 3 |
View Market Depth
| Last trade - 16.10pm 19/06/2024 (20 minute delay) ? |
| FPH (ASX) Chart |